Table 1.
Baseline demographic and clinical characteristics (N = 1940).
| Early favipiravir treatment (n = 1076) | Late favipiravir treatment (n = 864) | P value | |
|---|---|---|---|
| Male | 485 (45.1%) | 401 (46.4%) | .557 |
| Age (years) | 43.0 ± 15.1 | 40.8 ± 14.7 | .001 |
| Age > 60 years | 169 (15.7%) | 107 (12.4%) | .037 |
| BMI (kg/m2) | 25.4 ± 5.3 | 24.8 ± 5.1 | .02 |
| BW ≥ 90 kg | 87 (8.4%) | 46 (5.5%) | .016 |
| Vaccination status | <.001 | ||
| •Unvaccinated | 485 (47.5%) | 574 (69.8%) | |
| •Partially vaccinated | 333 (32.6%) | 161 (19.6%) | |
| •Vaccinated | 204 (20.0%) | 87 (10.6%) | |
| Symptomatic at presentation | 931 (86.5%) | 864 (100.0%) | <.001 |
| ≥ 1 comorbidities | 358 (33.3%) | 279 (32.3%) | .648 |
| •HT | 174 (8.1%) | 122 (6.3%) | .212 |
| •DM | 87 (16.2%) | 54 (14.1%) | .122 |
| •Lipid disorders | 67 (6.2%) | 45 (5.2%) | .339 |
| •Stroke | 7 (0.7%) | 5 (0.6%) | .841 |
| •CKD | 8 (0.7%) | 7 (0.8%) | .868 |
| RT-PCR cycle threshold | 21.5 ± 5.9 | 22.8 ± 5.2 | <.001 |
| Time to start favipiravir after symptom onset (days) | 3.7 ± 1.2 | 7.9 ± 1.9 | <.001 |
BMI = body mass index, BW = body weight, CKD = chronic kidney disease, DM = diabetes mellitus, HT = hypertension, kg = kilograms, m2 = square meter, RT-PCR = reverse transcription-polymerase chain reaction.